Neurology

Your Article Summary

See Latest Articles

Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
Expert Opinion on Investigational Drugs, 09/22/09

Dietrich J et al. – Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09

Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

See All of Neuro/Psych pharmacology

Today in Neurologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
Journal of Clinical Oncology, 11/12/09

Clinical Analysis of Novalis Stereotactic Radiosurgery for Brain Metastases
Journal of Korean Neurosurgical Society, 10/30/09

See All of Neurologic Oncology